Xenoview-Hyperpolarized Xe-129
Xenoview provided a functional alternative in lung imaging, where standard scans show structure well but reveal little about which regions actually ventilate. Its xenon nuclei are hyperpolarized to make them detectable by MRI, producing regional ventilation maps without ionizing radiation. Inhaled during a single breath hold, it is approved for MRI evaluation of lung ventilation […]
Sunlenca-Lenacapavir
Sunlenca (lenacapavir) introduced an entirely new mechanism for patients with multidrug-resistant HIV, who can exhaust every available class and be left without a viable regimen. As the first capsid inhibitor approved, it disrupts multiple stages of the viral lifecycle, so no existing resistance pathway applies. Subcutaneous injections every six months follow oral loading, used with […]
Krazati-Adagrasib
Krazati (adagrasib) followed sotorasib into the KRAS G12C space, arriving as the second approved inhibitor of a target once considered undruggable. Adagrasib binds the mutant protein irreversibly and covalently, and its longer half-life and central nervous system penetration distinguish it pharmacologically from sotorasib. The twice-daily tablet treats adults with KRAS G12C-mutated locally advanced or metastatic […]
Rezlidhia-Olutasidenib
IDH1 mutations occur in a small share of acute myeloid leukemia and block normal blood cell maturation. Rezlidhia (olutasidenib) added a second targeted option for these patients. Olutasidenib inhibits the mutant IDH1 enzyme, lowering the oncometabolite 2-hydroxyglutarate so immature leukemia cells can resume normal differentiation. The twice-daily capsule treats adults with relapsed or refractory acute […]
Imjudo-Tremelimumab
Unresectable hepatocellular carcinoma moved rapidly toward immunotherapy combinations, and the challenge was capturing CTLA-4 benefit without its cumulative toxicity. Imjudo (tremelimumab) was approved in a regimen built around that. Given as a single priming dose alongside ongoing durvalumab, this CTLA-4 blocking antibody broadens the T-cell response once rather than exposing patients to repeated CTLA-4 dosing. […]
Lytgobi-Futibatinib
FGFR2 fusion-positive cholangiocarcinoma became one of the first biomarker-defined niches in bile duct cancer, and acquired resistance to reversible inhibitors emerged quickly. Lytgobi (futibatinib) took a covalent approach. Futibatinib binds FGFR irreversibly and covalently, preserving activity against some resistance mutations that defeat reversible inhibitors. The once-daily tablet treats previously treated, unresectable locally advanced or metastatic […]
Relyvrio-Sodium Phenylbutyrate/Taurursodiol
ALS has one of the highest-profile unmet needs in neurology, and Relyvrio’s approval became a defining test of how much regulatory flexibility that justifies. The oral powder combined sodium phenylbutyrate and taurursodiol, intended to slow motor neuron death by easing endoplasmic reticulum and mitochondrial stress. Approval for amyotrophic lateral sclerosis rested on a small phase […]
Omlonti-Oomidenepag Isopropyl Ophthalmic Solution
Prostaglandin analogs are first-line for glaucoma, but a meaningful share of patients respond poorly or cannot tolerate them. Omlonti (omidenepag isopropyl) works through a different prostaglandin receptor. Unlike FP-receptor prostaglandin analogs that act mainly on one route, Omlonti increases aqueous outflow through both the trabecular and uveoscleral pathways as the first selective EP2 receptor agonist […]
Elucirem-Gadopiclenol
Gadolinium retention concerns have pushed MRI contrast toward using as little gadolinium as diagnostically possible. Elucirem (gadopiclenol) was designed for exactly that. Its relaxivity is roughly double that of conventional agents, allowing comparable image quality at half the standard gadolinium dose. The macrocyclic contrast agent is used with MRI to detect and visualize lesions with […]
Terlivaz-Terlipressin
Terlivaz finally brought terlipressin to the American market, where clinicians had long relied on off-label vasoconstrictor combinations for hepatorenal syndrome while it was standard elsewhere. As a vasopressin V1 receptor agonist, it constricts splanchnic blood vessels to raise effective arterial volume and restore perfusion to the kidneys. The intravenous therapy improves kidney function in adults […]
